Listed Companies
Latest Results
Annual / Interim Reports
Announcements
Press Releases
Company Presentations
Upcoming Events
Corporate Governance
Prospectuses / Circulars
Register with Companies
Stock Quotes
IPO Information
ADR / OTCQX Search
NEW on irasia.com
FREE Email Alerts
Latest Results
Annual / Interim Reports
Announcements
Press Releases
Company Presentations
Upcoming Events
Corporate Governance
Prospectuses / Circulars
Register with Companies
Stock Quotes
IPO Information
ADR / OTCQX Search
NEW on irasia.com
FREE Email Alerts
Neuren Pharmaceuticals Limited
Press Releases
You will need the Adobe Acrobat Reader 7.0 to view the PDF.
If you do not have any of the above, please download "Acrobat Reader".
| Neuren Scientist Receives NZ's First Laureate Award for Scientific Excellence (in PDF) | |
| Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment (in PDF) | |
| US FDA Approves Neuren's Phase 3 IND for Glypromate® Trial (in PDF) | |
| Neuren Reports Successful NNZ-2566 Safety Trial Results (in PDF) | |
| 2006 Press Releases |
| © Copyright 1996-2008 irasia.com Ltd. All rights reserved. Tel: (852) 2831-9792. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |